相关临床试验
227
92 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1974
进行中（未招募）
20
8.8%
已完成
76
33.5%
尚未招募
72
31.7%
招募中
53
23.4%
终止
3
1.3%
撤回
3
1.3%
暂无批准数据
- Researchers from IIT Madras, Monash University, and Deakin University have developed a novel nanoinjection drug delivery platform that combines nanoarchaeosome-based drug encapsulation with silicon nanotube technology for targeted breast cancer treatment. - The NAD-SiNTs platform demonstrated 23 times lower inhibitory concentration than free doxorubicin while inducing strong cytotoxicity against MCF-7 breast cancer cells and sparing healthy fibroblasts. - The system provides sustained drug release for up to 700 hours and significantly reduces angiogenesis by downregulating key pro-angiogenic factors, potentially making cancer treatment safer and more cost-effective. - The technology has completed successful proof-of-concept validation in cell culture and chick embryo models, with clinical translation expected within five years.
- Australian researchers at RMIT University have developed experimental eyedrops using nano-cubosome technology to deliver lutein directly to the retina, potentially replacing painful eye injections for treating age-related macular degeneration and diabetic retinopathy. - The innovative delivery system uses cubosomes as tiny shields to protect lutein and release it in a controlled manner, successfully reaching retinal tissue in mouse studies and remaining stable at room temperature for months. - In laboratory tests, the lutein-loaded eyedrops reduced toxic compounds VEGF-A and IL-6 in retinal cells by activating the Nrf2/HO-1 antioxidant pathway, demonstrating potential therapeutic benefits. - While promising, the research remains in early stages with testing conducted only on healthy mice and cell cultures, requiring further animal studies and eventual human trials before clinical application.
